Study #2025-1671
A Phase 1, Multicenter, Open-Label, Non-Randomized, Dose-Escalation And Backfill Study Of KK2223 In Participants With Relapsed Or Refractory T-Cell Non-Hodgkin Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
KK2223
Description
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
T-cell NHL (PTCL or CTCL)
Study phase:
Phase I
Physician name:
Ranjit Nair
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.